Goldman Sachs
DNLI icon

Goldman Sachs’s Denali Therapeutics DNLI Stock Holding History

Goldman Sachs’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,000
Closed -$2.35M – 6285
2021
Q2 		$2.35M Buy
+30,000
New +$1.86M ﹤0.01% 4050

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs's DNLI Position: Q1 2026 in Review

Goldman Sachs increased its Denali Therapeutics (DNLI) stake by 15% in Q1 2026, buying an estimated $11.4M and bringing the position to 4,407,255 shares worth $84.6M. The position accounts for 0.01% of the portfolio, ranked #1157.

Goldman Sachs first reported a position in DNLI in Q4 2017 and has held it in 34 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Goldman Sachs held 4,407,255 shares of Denali Therapeutics worth $84.6M as of Q1 2026.
  • Goldman Sachs bought 571,452 Denali Therapeutics shares in Q1 2026, an estimated $11.4M.
  • Denali Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1157 holding.
  • Goldman Sachs first reported a position in Denali Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.